MSD's tulisokibart is already in phase 3 testing, while Roche's RG6631 (formerly RVT-3101) is scheduled to start phase 3 before the end of this year. In RELIEVE UCCD, 36.2% of UC patients treated ...
Neural Reactive Natural IgMs & the Nature of Neural Surface Antigens How B cells are activated to secrete antibodies that recognize self-antigens of the nervous system remains unknown. The ...
Personalized Medicine. 2015;12(2):139-154. Table 1. Poly-(ADP-ribose) polymerase inhibitors in clinical studies. PARP inhibitor Number of completed or ongoing studies Type of studies completed or ...
As the trend towards the international dispersion of certain value chain activities produces challenges, discover policies to meet these Tax transparency and international co-operation Enhanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback